A major clinical trial demonstrates successful gene editing treatment for β-thalassaemia using an improved CRISPR/Cas9 system that produces more precise edits with fewer errors. This breakthrough follows the recent FDA approval of CRISPR therapy for sickle-cell anemia and represents significant progress in treating genetic blood disorders. The Chinese research team developed a more targeted approach that reduces off-target effects while effectively addressing the underlying genetic cause of β-thalassaemia.
Background
CRISPR/Cas9 gene editing technology has been developing for decades, with the first FDA-approved therapy for sickle-cell anemia arriving just two years ago. The technology works by using guide RNAs to target specific DNA sequences for cutting and editing.
- Source
- Ars Technica
- Published
- Apr 10, 2026 at 04:28 AM
- Score
- 8.0 / 10